underlining risk for a large number of loci has proceeded more slowly, at least in part, because of a lack of systematic assays to rapidly evaluate all SNPs present in the genomic region of interest for regulatory activity. The protocol described here is designed to fill this gap.
To comprehensively capture the initial set of candidate functional SNPs to be tested, it is acceptable to sacrifice specificity to obtain higher sensitivity. This initial step should capture most true positive signals. Then, downstream analysis using stringent criteria (e.g., allele-specific effects are shown in vitro and in vivo) will progressively eliminate false positive signals. Assays based on naked (or nonchromatinized) DNA such as electrophoretic mobility shift assays (EMSAs) or luciferase reporter assays are particularly suited for this step, as they will identify any putative active sequence in the underlying DNA, provided that the required factors are expressed in the cell of interest 10 .
To accelerate discovery and functional analysis of GWAS loci, we developed a streamlined method that can systematically scan for regions with regulatory activity in a cell line of choice and can be scaled-up to study relatively large genomic regions (100-500 kb). The method takes advantage of online bioinformatics tools and combines a PCR-based generation of tiling clones spanning the region with high-efficiency recombination cloning. This method has been used successfully in the analysis of loci associated with ovarian 11 , brain 12 and breast (G.M.-F., unpublished data) cancer predisposition.
Functional Annotation of the Mammalian Genome (FANTOM) consortium 19, 20 . Data from these initiatives can be used to identify SNPs that overlap with chromatin features and that are more likely to be functional. In this case, our method can provide additional validation, as well as a means to test whether different alleles of the SNP may lead to changes in activity.
In addition, as regulatory region activity may depend on the presence of cell type-specific transcription factors or certain stimuli 15 , ENCODE data may not be available for specific cell types and conditions that are relevant to the investigator's experimental question. For example, a significant number of cell types in ENCODE are cancer cell lines, but ideally analysis of loci implicated in predisposition should be performed in the normal cell from the tissue of origin of the cancer being studied 3 . Thus, our method can be applied to primary (or immortalized) normal cell lines to complement or add to ENCODE data.
In some cases, SNPs located in a coding region might also have a simultaneous effect on a regulatory motif 21 . These coding regions can also be tested in our method for regulatory activity. Finally, although the method is primarily geared to analyze germline variants, it can be applied to perform functional analysis of variants found in noncoding regions derived from whole-genome or targeted clinical sequencing efforts of tumor DNA 22 .
Alternative methods
Two recently published methods, massively parallel reporter assay (MPRA) and self-transcribing active regulatory region sequencing (STARR-seq), are also designed to identify regions of regulatory activity 23, 24 . MPRA, STARR-seq and the method presented here measure regulatory activity in a nonchromatinized plasmidbased DNA template and require a cell host with high transfection efficiency. MPRA and STARR-seq are based on libraries of synthesized oligonucleotides or bacterial artificial chromosome (BAC) fragments, respectively. Although both MPRA and STARRseq can interrogate a much larger number of candidate regulatory segments per experiment than our method, they also require the generation of high-complexity representative libraries involving several additional steps of quality control 23, 24 . Currently, highcomplexity representative libraries of mammalian genomes are limited to six BACs in STARR-seq 24 . In combination with sequencing data analysis required to identify regulatory segments, MPRA and STARR-seq require more experienced investigators and significantly more time for optimization. MPRA is designed to test the activity of relatively short sequences (87 nt) 23 ; although it is ideal to identify optimal sequences for specific transcription binding sites, it may be unable to detect regulatory activity from longer sequences that depend on cooperative binding of different transcription factors. Thus, we believe that our method provides an alternative to investigators who are conducting an analysis focusing on one or a few loci. Investigators looking to perform analysis of multiple genomic loci are encouraged to compare MPRA, STARR-seq and enhancer scanning to decide which method is most appropriate for their project scope, level of experience and resources.
Limitations
The enhancer scanning method presented here is based on the use of a plasmid-based reporter gene to detect regions in the genomic DNA with transcriptional regulatory activity. Similarly to other naked DNA-based assays (such as EMSAs), it identifies sequences present in the DNA that have the ability to recruit and bind transcriptional regulators. It is conceivable that the underlying DNA (exposed in the plasmid-based assay) that carries the activity may, in certain chromatin contexts, be hidden by tight nucleosome packing, repressive chromatin features and DNA methylation. Thus, some tiles may be false positive hits. In addition, some amplicons with repeats may be especially difficult or impossible to amplify, and therefore they may not be able to be tested using this method.
Although we have identified tiles with repressive activity (i.e., display a fold reduction in relation to the negative empty vector control), we have not characterized these in detail to determine whether they represent true repressive regions, as many of them do not colocalize with ENCODE chromatin features suggestive of repression, such as CCCTC-binding factor (also known as CTCF) ChIP-seq peaks. Thus, further work is needed to determine whether this method is appropriate to identify repressive regions.
The sensitivity of the method presented here is dependent on transfection efficiency, and cells that are difficult to transfect, or experiments in which transfection is suboptimal, may not identify all tiles with activity. The use of a set of internal controls greatly minimizes false negatives resulting from transfection failures. The ability of the enhancer to activate transcription of a cognate promoter region depends of the formation of an adequate DNA loop between the enhancer and the promoter 25 . Thus, it is conceivable that, even when testing both cloning orientations in a plasmid context, an optimal loop may not form between the region and the promoter, leading to false negative results. To estimate the fraction of false negatives, in the absence of a well-characterized region to use as a benchmark, we determined the number of active enhancers as defined by ENCODE biofeatures that were not positive according to the enhancer scanning method. In our experience, ~15% of tiles predicted by ENCODE biofeatures failed to show activity in enhancer scanning (a similar fraction was found using STARR-seq; data not shown). However, this number may not necessarily reflect false negative regions, because cells chosen for enhancer scanning were not the exact same cell types used to obtain ENCODE biofeatures. Moreover, some regulatory regions may be dynamic, and they may shift from active to inactive during cell culture.
Finally, it is unclear to what extent the detection of a regulatory activity using a heterologous promoter affects the results. Although most enhancers function with any promoter 10 , some enhancer-promoter interaction depends on binding factors or other promoter features (biochemical compatibility) 26 . Thus, in the case of post-GWASs, in which several promoters in the region might be potential targets, we suggest using the viral promoter for the first screen. Once the target gene is identified (by expression quantitative trait loci analysis or chromosome conformation capture techniques), a tile can be tested again with the desired promoter.
Experimental design
The complete procedure is depicted in Figures 1 and 2 . Essentially, we start with a genomic region identified by a GWAS, as associated with the risk for a certain condition (Fig. 2a) , and we assume that the tagging SNP may not necessarily represent the functional SNP. Next, in order to capture the variation in the locus, we can use LD structure information and retrieve all SNPs in LD with the tagging SNP ( Fig. 2b ; Steps 1-6) 27, 28 . As a rule of thumb, we retrieve sets of SNPs in LD in data from the 1000 Genomes Project with r 2 ≥ 0.2, ≥0.5 or ≥0.8. These thresholds are arbitrary, and they serve as a guideline for the investigator to decide which set to pursue further analysis appropriate for the resources and time available. When fine-mapping data are available (Fig. 2c) , investigators may want to identify the region that contains all the statistically significant SNPs. Alternatively, prioritizing SNPs with a likelihood ratio (relative to the the most significantly associated SNP) of >1:100 (or >1:1,000) can reduce the number of SNPs to be analyzed 29 . The region of interest is delimited by the most telomeric and the most centromeric SNPs flanking the set (Fig. 2c) .
With the region of interest defined, we generate tiles by PCR-spanning the whole region with each tile of ~2 kb ( Fig. 2c ; . This size is a compromise between having to generate the fewest tiles to cover a region and efficient and reproducible PCR amplification. Regions with repetitive sequences may need smaller tiles to facilitate amplification. The PCR primers used are designed to include attL sequences to mediate recombinational cloning into destination vectors, pGL3-LRF and pGL3-LRR (Fig. 3) , which contain a luciferase gene driven by a basal promoter (Fig. 1) . We converted the pGL3-promoter vector (Promega) to a Gateway destination vector by inserting a blunt-ended cassette of the ccdB gene and the chloramphenicol resistance gene flanked by attR1 (5′-ACAA GTTTGTACAAAAAAGCTGAAC-3′) and attR2 (5′-GACCACT TTGTACAAGAAAGCTGAAC-3′) sites into a SmaI site of pGL3-promoter vector (Fig. 3) . Two recombinant vectors, carrying the cassette in each orientation, pGL3-LRF and pGL3-LRR, are then used to clone individual tiling clones by recombination (Steps 12-27). Plasmids containing tiling clones in both orientations are then transfected in an appropriate cell type, and the activity of luciferase is measured and compared with the corresponding pGL3-LR destination vector (Fig. 1 , bottom right; Steps 28-50). Alternatively, inserting a tile into the pGL3-promoter vector can be done by conventional cloning using restriction digestion and ligation (Step 10). In this case, the PCR primers used to amplify each tile should contain the desired restriction site present in the multiple cloning site (KpnI, SacI, MluI, NheI, XhoI and BglII; Step 10).
To be considered a candidate functional SNP, we expect tiles containing different alleles to show statistically significant differences (P ≤ 0.05) in reporter activation. If the method is used to validate regions suggested by analysis of ChIP-seq or formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq) data, a complete tiling of the whole region is not necessary and only tiles overlapping desired features can be generated, which greatly reduces the number of tiles to test (Fig. 2c) . Tools such as RegulomeDB and FunciSNP can identify which SNPs overlap with data from ENCODE or other sources 30, 31 . Here we use the classic operational definition of transcriptional enhancer as 'discrete DNA elements that contain specific sequence motifs with which DNA-binding proteins interact and transmit molecular signals to genes' 32 . ENCODE data show that chromatin features of enhancers are that they are located in DNase I hypersensitive regions that contain high levels of H3K4me1 (histone H3 lysine 4 monomethylation) in relation to H3K4me3 (trimethylation) 15, 33 . Although enhancers are expected to operate independent of orientation and position relative to the target promoter 34 , because the relative position of the binding site in relation to the promoter of the reporter may influence expression, tiles should be tested in both cloning orientations (Fig. 2d) .
True functional SNPs are also expected to show allelespecific differences in enhancer activity. Risk alleles may create or disrupt a specific binding site, and it is recommended to test both alleles for each SNP. Different alleles can be introduced in the tiles using QuikChange PCR mutagenesis 35 (Steps 51-53). Sanger sequencing, using the universal primers RVprimer3 and GLprimer2 (Promega), is recommended for verifying the variant after mutagenesis. Additional primers may be necessary to cover the entire region, and they should be designed ~100 bp from the start of the region to be sequenced.
Choice of template, tile verification and host cell
Once the region of interest is defined, we generate tiles by PCR using human genomic DNA or a BAC clone containing the region of interest (Fig. 1) . In our experience, the latter provides a more robust option to amplify the tiles. It is expected that the BAC is likely to contain the major allele for the SNPs, but it could represent the minor allele. In addition, depending on the number of loci being studied and the size of regions to be analyzed, there could be hundreds of tiling clones to be processed simultaneously, which increases the chance of sample mix-ups. Thus, it is useful to sequence a sample (or all) of the clones to confirm their identity and to determine the correct allele being tested.
Ideally, the host cell for the transfection should represent a tissue compartment that is relevant to the disease under study: for example, cells from normal intestinal crypts when studying colorectal cancer. However, primary cells might be difficult to transfect and immortalized or cancer cells may provide an alternative, but the use of these cell lines should be kept in mind when interpreting the results.
Controls
Several controls are advisable to guarantee data quality and wise use of resources and reagents. We found that because in each experiment a large number of luciferase measurements are going to be made it is important to monitor whether the transfection has worked before processing samples. We recommend the use of a parallel transfection with a GFP expression vector of choice, and when there are no detectable GFPpositive cells we do not proceed to lysing cells and measuring luciferase. We also include a positive control (pGL3-control vector containing with a simian virus 40 (SV40) enhancer) and expect its activity to be consistent across transfections (10-20× the negative control in the experiment, for example). Eight technical replicates are performed for each tile in each orientation, and luciferase readings are averaged and compared with the negative control. The negative controls used are the plasmids that only include the recombination cassette in both orientations, and they are compared with the tested tiles of the same orientation. An additional control derived from the region being studied is also recommended, and it can be designed by identifying a region with no candidate SNPs and with no chromatin markers indicative of activity. We recommend the inclusion of all controls in every plate. As a rule of thumb, we perform at least two independent experiments that are typically done on different days (biological replicates); only tiles that have significant activity in both biological replicates are considered for further analysis.
As the goal is the identification of functional SNPs, confirmation by sequencing of the desired clone is an absolute requirement. Even when starting from a template of known genotype (BAC or a genotyped cell line genomic DNA) and using a proofreading polymerase, cross-contamination is possible, as are very rare PCR errors. When starting from a genomic DNA template of unknown genotype or using non-proofreading polymerase, -log 10 (P) we recommend sequencing all clones, which might add to cost and should be taken into consideration when deciding which polymerase to use.
Statistical analysis
Results from transfections with individual tiles are analyzed in eight replicates. This number allows for the generation of box whisker plots, and it maximizes the 96-well setup, but investigators might want to scale it down to reduce costs. Raw readings from firefly (Photinus pyralis) luciferase are normalized against an internal Renilla reniformis luciferase control driven by a minimal promoter pRL-TK (Renilla luciferase driven by the thymidine kinase promoter) to adjust for differences in transfection efficiency in different wells. Next, we set the negative control (pGL3-LRF and pGL3-LRR empty vectors) as the reference, and results are transformed to fold changes relative to the negative control. Statistical analysis is performed by comparing the exact means, and P ≤ 0.05 is considered significant. When testing a large number of tiles, a multiple testing correction can be applied (for example, P ≤ 0.05 divided by the number of tiles being tested). Alternatively, a less-stringent false discovery rate can also be applied for prioritization. However, we feel that because of the stage of SNP analysis in which this assay is being performed, it would be unwarranted to apply multiple testing corrections, as true positive clones with small effects might be discarded. Additional, more-stringent tests are subsequently applied to the tiles (allele-specific differences, activity in EMSA and so on) to weed out false positive hits. Total volume (µl) 50
HotStarTaq PCR conditions
Step 
medium, and avoid touching the plastic walls of the tube. Chemical residues in plastic vials can markedly decrease the biological activity of the reagent.
Add 35 µl of internal control, pRL-TK, at 10 ng/µl.
Next, make master mix 2 (MM2) for 12 reactions (columns) per plate; each reaction should to be distributed into eight wells (rows) each + two for extra volume (Fig. 4) . Divide the solution into 40-µl aliquots of each test plasmid at a concentration of 25 ng/µl into 12 Eppendorf tubes. ! cautIon In order to compare activities of different tiles, plasmids containing different tiles should be transfected in the same molarity. As all our tiles are designed to have the same ~2 kb, the same DNA concentration can be used in every transfection. However, when clones contain tiles of variable size, concentrations should be adjusted to have the same molarity in every reaction. In this case, use carrier DNA (salmon sperm) to adjust the total amount of DNA being transfected.
Add 60 µl of MM1 into each Eppendorf tube, and incubate the tubes at room temperature (RT; 25 °C) for 25 min; next, dispense 10 µl of MM2 into each well of the same column (e.g., wells A-H) Each column will therefore have eight replicates of the same plasmid. It is recommended to add all three controls to every plate: pGFP (for transfection efficiency), pGL3-control vector (positive control containing SV40 enhancer) and pGL3-LRR or pGL3-LRF (negative controls; empty destination vectors containing the ccdB cassette but no enhancer). Although we transfect eight wells with pGFP, this is only for convenience when preparing the master mixes, and fewer wells (e.g., four) are enough to monitor transfection and you may reduce the volume of the master mix for that transfection only.
EQUIPMENT SETUP Setup for luminometer (SpectraMax L) reading (Step 37)
See Box 1.
Transfection reaction setup (Steps 32-34)
We have tested FuGENE 6, FuGENE HD, Lipofectamine 2000 and Lipofectamine 3000 in at least ten different cell lines. All transfection reagents were efficient in at least one cell type, and results were cell type dependent. Here we provide a Setup using FuGENE HD, because it was effective across more cell types. Immortalized primary cell lines are generally more difficult to achieve high transfection efficiency. For these cell lines, we have obtained high transfection efficiency using Nucleofection (Lonza). To make master mix 1 (MM1) for a 96-well plate, 14 reactions (12 + 2 for extra volume; Fig. 4) , first combine in one tube 762 µl of medium, and then add 43 µl of FuGENE HD. Pipette it directly into the (ii) Click on the 'LDProxy' tab and enter the SNP(s) rsid (reference SNP cluster ID) number(s) on the left and select the desired populations (those used in the GWASs of interest) from the dropdown box (i.e., 'CEU'). (iii) Click 'Calculate' to obtain the LDProxy output. The output provides an interactive graph that plots the r 2 values of proxy SNPs and combined recombination rate against genomic coordinates. Each SNP is shown as a circle with a number inside corresponding to the RegulomeDB score for that SNP. Hover over the SNP to view more information. (iv) Click 'Download all proxy SNPs' at the bottom of the page to download a text (.txt) file with genomic coordinates in University of California, Santa Cruz (UCSC) version hg19 (National Center for Biotechnology Information (NCBI) build GRCh37) format, so that these can be used to create a custom .bed file to be displayed on the UCSC Genome Browser. plink --vcf genotypes -r2 --ld-snp rs3814113 --ld-window-kb 500 -ld-window 99999 -ld-window-r2 0.2 --out rs3814113_calculations
plink --vcf genotypes -r2 --ld-snp-list snp_list.txt --ld-window-kb 500 -ldwindow 99999 -ld-window-r2 0.2 --out list_calculations  crItIcal step The VCF option is only available for version 1.9, which is available for download at http://pngu.mgh. harvard.edu/~purcell/plink/plink2.shtml. Previous versions require PED and MAP files. The 1000 Genomes Project provides the VCF-to-PED converter tool at http://browser.1000genomes.org/Homo_sapiens/UserData/Haploview?db=core. PED and INFO files can be downloaded from the converter tool, and they require slight reformatting (i.e., the chromosome column needs to be added to the INFO file for MAP format) to use in PLINK for LD calculations. 
4|
Choose appropriate BAC(s) covering the region of interest, and click on them to obtain BAC information. Click on the BAC designation to be directed to the NCBI's Clone DB record for the BAC, click on the 'Distributors' tab to choose a supplier, and then order BAC from your supplier of choice for use in Step 12A.  crItIcal step Genomic DNA from cell lines can also be used as template to amplify tiles (see Step 12B), but using BACs increases the success rate and diminishes specificity issues.
5|
Return to the browser window showing your region. Under 'View', on the top menu bar, click on 'DNA' . Verify that the region shown matches the coordinates of your region. By using the boxes under 'Sequence Retrieval Options', add 2,000 extra bases to each side of the region: for example, 'Add [2,000] extra bases upstream (5′) and [2, 000] 
extra downstream (3′)'
6| Click on 'get DNA' . This will generate a FASTA file with the nucleotide sequence for your region.
primer design • tIMInG ~4 h 7| Go to PCRTiler (http://pcrtiler.alaingervais.org:8080/PCRTiler/) and input your sequence from Step 6. For primer parameters, we use minimum primer Tm = 57; maximum primer = 63; and amplicon range between 1,800 and 2,300. For tiling parameters, check 'Design a primer pair at each X base pairs, where X is' and enter 1800. If you are using BAC as a template (see Step 12A), check 'Skip the specificity check' . This will generate a list of primer pairs to amplify the tiles.
8|
Go to the Human Genome Browser Gateway (http://genome.ucsc.edu/cgi-bin/hgGateway) and under 'Tools', on the top menu bar, click on 'In silico PCR' . In the 'Genome' pull-down menu, select 'Human'; in the 'Assembly' menu, select 'Feb. 2009 (GRCh 37/hg19)'; and in the 'Target' menu, select 'genome assembly' . For 'Max Product Size', 'Min Perfect Match' and 'Min Good Match' retain default values. For each PCR primer pair from Step 7, copy and paste each sequence in the 'Forward Primer' and 'Reverse Primer' boxes. Click 'submit' . Obtain the coordinates for your tiles defined by the PCR primers from the header line (it will be the first line, indicated by a '>' sign) of the FASTA file:
>chr22:31000551+31001000 TAACAGATTGATGATGCATGAAATGGG CCCATGAGTGGCTCCTAAAGCAGCTGC Add the data to an excel spreadsheet in BED file format, as follows:
9| Create a Human Genome Browser private session to keep track of your tiles. Under 'My Data' on the top menu bar, click on 'sessions' and follow the instructions to create your session. Create a custom track and upload your BED file from
Step 8 into your session in the genome browser.
10|
To design primers to generate tiles by recombination, add LR recombination sites (attL1 5′-CCAACTTTGTACAAAAAAGCAGGCT-3′ and attL2 5′-CCAACTTTGTACAAFAAAGCTGGGT-3) and MluI (ACGCGT) and XhoI (CTCGAG) restriction sites to attL1 and attL2, respectively, to the 5′end of the primers. ! cautIon Some restriction enzymes are not efficient at cutting close to the end of the PCR product. We recommend consulting the New England Biolabs guide to cleave close to the end of DNA fragments (https://www.neb.com/tools-andresources/usage-guidelines/cleavage-close-to-the-end-of-dna-fragments) before designing primers. If you conduct traditional cloning, your empty vector control should be pGL3-promoter.  crItIcal step Alternatively, primers can be designed to generate tiles by traditional cloning. PCR primers to amplify each tile should contain the desired restriction site present in the multiple cloning site (KpnI, SacI, MluI, NheI, XhoI and BglII). For example, a forward primer would contain a KpnI site and a reverse primer would contain a BglII site. To test all tiles in both orientations, PCR primers for this example would also be generated with a BglII site in the forward primer and a KpnI site in the reverse primer. The generation of clones by recombination is substantially more efficient than traditional restriction digest cloning.
11|
Order primers containing LR recombination sites and restriction digest sites. To save time, you may choose to start culturing cells for cDNA isolation or order BAC clones at this stage (see Step 12) .  pause poInt Work can restart when BACs and primers are received.
tile generation • tIMInG ~2 weeks 12| Obtain BAC DNA (option A) or genomic DNA (option B) to use as template to generate tiles by PCR amplification (a) Bac Dna (i) Inoculate an aliquot of the glycerol stock of Escherichia coli containing the BAC DNA into 50-100 ml of LB containing the appropriate antibiotic for selection, and incubate it with shaking (at 300 r.p.m.) overnight at 37 °C. (ii) Isolate BAC DNA using the HiSpeed plasmid maxi kit or plasmid maxi kit according to the manufacturer's instructions.
In our hands, both kits yield similar results.  crItIcal step The large-construct kit can also be used, but, in our experience, the yield is seldom satisfactory.
? trouBlesHootInG (B) Genomic Dna (i) Grow one or two 100-mm plates of a human cell line and collect cells to isolate genomic DNA. We recommend the use of normal primary or immortalized cells to avoid possible problems with genomic alterations in cancer cell lines. ! cautIon We recommend avoiding cell lines that are commonly misidentified or cross-contaminated (http://iclac. org/databases/cross-contaminations/). Cell lines should be regularly checked for authenticity (for example, using short tandem repeat authentication) and for Mycoplasma contamination. (ii) Isolate human genomic DNA using the PureLink genomic DNA mini kit, according to the manufacturer's instructions.
13| Perform PCR to amplify tiles (see Reagent Setup for reaction conditions); use 50 ng of BAC DNA from Step 12A(ii) or amend volumes shown to allow for 100 ng if you are using genomic DNA from Step 12B(ii). ! cautIon Be extremely careful when manipulating primers for these experiments to avoid cross-contamination.
14|
Perform electrophoresis on PCR products on a 1% (wt/vol) agarose gel for size documentation and for gel purification. The recommended voltage is 4-10 V/cm of distance between the electrodes. For confirmation and size documentation, run 5 µl of PCR product with 1 µl of 6× gel loading buffer. For gel purification, run the remaining 20 µl (for KAPA HiFi; or 45 µl for HotStart Taq) of PCR product and 4 µl of 6× gel loading buffer. Purify PCR products using the QIAquick gel purification kit according to the manufacturer's instructions. ? trouBlesHootInG 15| To clone each tile in both orientations, mix 7 µl of the PCR product with 1 µl (150 ng) of pGL3-LRR in one Eppendorf tube; in a separate Eppendorf tube, mix 7 µl of PCR product with 1 µl (150 ng) of pGL3-LRF.
16|
Thaw the LR Clonase enzyme mix on ice and add 2 µl to the reaction from Step 15, mix well by vortexing briefly twice and incubate for 3 h to overnight at 25 °C.
17| Add 1 µl of proteinase K to each sample, and incubate the samples at 37 °C for 10 min.
tile cloning • tIMInG ~1 week 18| Transform 50 µl of competent TOP10 E. coli using 5 µl of each LR reaction from Step 17. In our experience, this reaction is successful >93%. Take this opportunity to transform, in parallel, all plasmids needed for the transfection (pGFP; pRL-CMV Renilla; pGL3-LR and pGL3-LR-ENH) in addition to the tiling clones. For these plasmids, use 1-5 µl of DNA (typically 10-50 ng) to transform 50 µl of competent TOP10 E. coli.
19|
Incubate on ice for 30 min.
20|
Heat-shock at 42 °C for 30 s.
21|
Add 250 µl of SOC medium and incubate at 37 °C for 1 h with shaking.
22| Plate 20 µl onto LB/agar ampicillin plates and grow the culture overnight in a 37 °C incubator. ? trouBlesHootInG 23| Pick one colony and grow it in 4 ml of medium in a 14-ml polypropylene round-bottom tube overnight.
24|
Isolate plasmid DNA using the Qiagen mini-prep kit to confirm the inserts.
25|
Digest the DNA with MluI and XhoI (see Reagent Setup for restriction enzyme digest conditions) for 1 h at 37 °C and run it on a 1% (wt/vol) agarose gel for verification. If the size of the insert is correct, make glycerol stocks of the transformants for future use. Add 500 µl of bacterial culture to 500 µl of sterile 50% (vol/vol) glycerol (in water) in a cryotube vial and mix. Freeze the tubes at −80 °C (tubes can be stored for several years).
26|
Sequence the clones to confirm both strands using pGL3-seq-rev and RVprimer3. Additional internal primers specific to each region may need to be designed to cover the entire region and to verify the SNP allele.  pause poInt Glycerol bacterial stocks or plasmid DNA can be stored for several years at −80 °C.
27|
Bring all plasmid DNAs to 25 ng/µl with water to prepare for transfection. Freeze them at −20 °C.  crItIcal step All plasmids to be compared in the same batch of luciferase assays must be prepped the same day (including controls). We have found that the same plasmid prepared in different batches (e.g., grown on separate days or stored for different lengths of time) may differ significantly in activity when transfected in parallel 37 . Figure 4 . We recommend setting up one plate at a time; handling multiple plates may lead to variation in incubation times.
30|
Prepare test plasmids (pGL3-LR and pGL3-LR-ENH control plasmids, pGL3 constructs containing the desired tiles) at a concentration of 25 ng/µl, and prepare internal control (pRL-CMV Renilla) at a concentration of 10 ng/µl. 34| Dispense 10 µl of MM2 into each well of the same column (e.g., wells A-H). Incubate for 24 h.  crItIcal step Because many tiles in different orientations and eight replicates are being analyzed, it is important to gauge how well the transfection worked so that reagents are not wasted on a large transfection experiment that failed. We recommend the inclusion of a GFP-only transfection to monitor the general quality of transfection. In our experience, if no or very few cells are green, the transfection was inefficient and should be repeated. ? trouBlesHootInG 35| Day 3. Use Dual-Glo luciferase reagents to measure Renilla and firefly luciferase activity 24 h after transfection (see Equipment and Reagent Setup). For experiments with a large number of plates, keep the time between transfection and addition of luciferase assay buffers across plates consistent. Follow the manufacturer's protocol (Promega) to prepare the reagents. Use a multichannel pipette to add a volume of Dual-Glo luciferase reagent equal to the volume of the culture medium (50 µl per well).
31|

36|
Incubate the plate at RT for 20 min to allow cell lysis.
37|
After completing the setup for luminometer reading (Box 1), insert the plate with the Dual-Glo luciferase reagent in the luminometer. ! cautIon To prevent damage to the injectors, be sure to remove the plate cover before inserting the plate into the luminometer.
38|
Go to your protocol document and select the firefly plate to read first. Click 'Read' under the toolbar. Reading of a full 96-well plate takes ~20 min.
39|
Remove the plate, add the Dual-Glo Stop & Glo reagent, incubate for 10 min and insert the plate back into the luminometer. ! cautIon Make sure to remove the plate cover.
40|
Go to your protocol document and select the Renilla plate and click 'Read' . After the plate reading is finished, go to 'File' → 'Save' to save the readings. To export the readings, go to 'File' → 'Export' to export your data as a txt document.
41|
Obtain Firefly/Renilla luciferase ratios for each transfected well, and calculate the average of the eight wells for the empty vector (pGL3-LRR or pGL3-LRF). 
42|
46| Copy and paste your values from
Step 45 in a table listing as follows: empty vector, enhancer, sample 1, sample 2 and so on. Note that you can rename your new table by right-clicking on it. This will also change the name of the graph associated with those data.
47|
Next, on the left panel, click on the document under 'Graphs' . This will appear as 'Data 1' if you did not rename it.
Label the x and y axes titles by clicking on them. Note that you can edit almost anything on the graph by double-clicking or right-clicking on it.
48|
On the graph document, click on 'Analyze' icon on the toolbar; a new window will open. On the left panel, select 't tests' under 'Column Analysis' . On the right panel, select just the sample you are analyzing and the empty vector. Click 'OK' .
49|
In the next window, select 'unpaired' under 'experimental design', 'Yes' under 'Assume Gaussian Distribution' and 'unpaired t test' under Choose test. Click 'OK' . In the results page, pay attention to rows 8-10 to look for significant difference between the two compared values. The actual P value will be displayed along with the P value summary (or level of significance), and on row 10 it will display whether it is significant or not. The statistical threshold is P value ≤ 0.05.
50|
Repeat Steps 27-49. Tiles that are significant in two separate experiments performed on different days are considered positive for transcription activity.
Mutagenesis to test alternative allele • tIMInG ~2 weeks 51| Design primers for QuikChange mutagenesis. We recommend the Agilent link for QuikChange II, which offers video tutorials (http://www.genomics.agilent.com/en/Site-Directed-Mutagenesis/QuikChange-II/?cid=AG-PT-175&tabId=AG-PR-1161) and free access to a primer design program. For tiles with multiple SNPs, mutagenesis can be done for each individual SNP separately to tease out individual contributions.
52|
Perform QuikChange mutagenesis using the QuikChange II XL site-directed mutagenesis kit (Agilent) according to the manufacturer's instructions.
53| Return to
Step 18 and transform 50 µl of competent TOP10 E. coli using 5 µl of each QuikChange reaction and continue through Step 49, comparing tiles with the major allele with tiles with the minor allele (not with the empty vector as in initial experiments). If they show significant differences in activity, they will be considered to have allele-specific activity.
? trouBlesHootInG Troubleshooting advice can be found in table 1.
• tIMInG Steps 1-11, choice of the region and primer design: week 1, 1-2 d of hands-on effort. Steps 1-6, 4 h. For those with no experience with the use of the UCSC Human Genome Browser, it is highly recommended to follow the tutorial materials available (http://www.nature.com/scitable/ebooks/guide-to-the-ucsc-genome-browser-16569863). In this case, the user should estimate an additional 2-3 h for these steps. Steps 7-11, 4 h. Delivery for oligonucleotide primers may take from a few days to >1 week, depending on location. Steps 12-27, tile generation and cloning: weeks 2-4
Step 12A, 2 d with ~4 h of hands-on effort
Step 12B, 5 d with ~4 h of hands-on effort. Both Steps 12A and 12B can be performed while you wait for primer delivery. Repeat the reaction using the KAPA HiFi PCR kit. This polymerase is substantially more expensive, and it may be prohibitive to use it to amplify all tiles in a large-scale experiment. PCRs using genomic DNA as template are also more difficult and we recommend, when possible, to use BAC DNA as template, which also avoids specificity problems (other non-relevant regions in the genome being primed 
